Beta Drugs Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Beta Drugs heeft een totaal eigen vermogen van ₹1.8B en een totale schuld van ₹190.6M, wat de schuld-eigenvermogensverhouding op 10.5% brengt. De totale activa en totale passiva bedragen respectievelijk ₹2.9B en ₹1.1B. De EBIT Beta Drugs is ₹558.1M waardoor de rentedekking 27.2 is. Het heeft contanten en kortetermijnbeleggingen van ₹278.9M.
Belangrijke informatie
10.5%
Verhouding schuld/eigen vermogen
₹190.60m
Schuld
| Rente dekkingsratio | 27.2x |
| Contant | ₹278.87m |
| Aandelen | ₹1.81b |
| Totaal verplichtingen | ₹1.14b |
| Totaal activa | ₹2.95b |
Recente financiële gezondheidsupdates
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Recent updates
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge
Nov 08Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Aug 30Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%
Aug 30Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20
Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹2.1B ) BETA } overtreffen de korte termijn passiva ( ₹972.5M ).
Langlopende schulden: De kortetermijnactiva BETA ( ₹2.1B ) overtreffen de langetermijnschulden ( ₹164.0M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: BETA heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van BETA is de afgelopen 5 jaar gedaald van 32.5% naar 10.5%.
Schuldendekking: De schuld van BETA wordt goed gedekt door de operationele kasstroom ( 132.1% ).
Rentedekking: De rentebetalingen op de schuld van BETA worden goed gedekt door EBIT ( 27.2 x dekking).